Subtype
Childhood Low Grade Glioma
CI-CAN-00004877Explore in graph →
PediatricNon-malignant7 active trials21 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004877Explore in graph →
Clinical trials
44 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01089101 | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | active not recruiting | Phase 1 / Phase 2 | 217 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06666348 | Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK(MIRV) | recruiting | Phase 1 / Phase 2 | 50 | St. Justine's HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02359565 |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials
| active not recruiting |
| Phase 1 |
| 71 |
| National Cancer Institute (NCI)NIH |
| 2 |
| Jul 20, 2026 |
| clinicaltrials |